Switch theme
Sign up to access all valuation multiples
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
1968
n/a
LTM Revenue $65.3M
LTM EBITDA $16.6M
$504M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharmicell has a last 12-month revenue (LTM) of $65.3M and a last 12-month EBITDA of $16.6M.
In the most recent fiscal year, Pharmicell achieved revenue of $47.1M and an EBITDA of $6.9M.
Pharmicell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharmicell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $65.3M | XXX | $47.1M | XXX | XXX | XXX |
| Gross Profit | $30.6M | XXX | $15.5M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $16.6M | XXX | $6.9M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $14.2M | XXX | $3.4M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $13.8M | XXX | $4.6M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pharmicell's stock price is KRW 11740 (or $9).
Pharmicell has current market cap of KRW 704B (or $512M), and EV of KRW 694B (or $504M).
See Pharmicell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $504M | $512M | XXX | XXX | XXX | XXX | $0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pharmicell has market cap of $512M and EV of $504M.
Pharmicell's trades at 10.7x EV/Revenue multiple, and 73.6x EV/EBITDA.
Equity research analysts estimate Pharmicell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharmicell has a P/E ratio of 37.1x.
See valuation multiples for Pharmicell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $512M | XXX | $512M | XXX | XXX | XXX |
| EV (current) | $504M | XXX | $504M | XXX | XXX | XXX |
| EV/Revenue | 7.7x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | 30.3x | XXX | 73.6x | XXX | XXX | XXX |
| EV/EBIT | 35.6x | XXX | 149.0x | XXX | XXX | XXX |
| EV/Gross Profit | 16.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.1x | XXX | 111.3x | XXX | XXX | XXX |
| EV/FCF | 148.0x | XXX | -825.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharmicell's last 12 month revenue growth is 72%
Pharmicell's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Pharmicell's rule of 40 is 87% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharmicell's rule of X is 206% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pharmicell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 72% | XXX | 74% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 145% | XXX | 128% | XXX | XXX | XXX |
| Rule of 40 | 87% | XXX | 87% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 206% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharmicell acquired XXX companies to date.
Last acquisition by Pharmicell was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharmicell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pharmicell founded? | Pharmicell was founded in 1968. |
| Where is Pharmicell headquartered? | Pharmicell is headquartered in South Korea. |
| Who is the CEO of Pharmicell? | Pharmicell's CEO is Mr. Hyun-soo Kim. |
| Is Pharmicell publicy listed? | Yes, Pharmicell is a public company listed on KRX. |
| What is the stock symbol of Pharmicell? | Pharmicell trades under 005690 ticker. |
| When did Pharmicell go public? | Pharmicell went public in 1988. |
| Who are competitors of Pharmicell? | Similar companies to Pharmicell include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Pharmicell? | Pharmicell's current market cap is $512M |
| What is the current revenue of Pharmicell? | Pharmicell's last 12 months revenue is $65.3M. |
| What is the current revenue growth of Pharmicell? | Pharmicell revenue growth (NTM/LTM) is 72%. |
| What is the current EV/Revenue multiple of Pharmicell? | Current revenue multiple of Pharmicell is 7.7x. |
| Is Pharmicell profitable? | Yes, Pharmicell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharmicell? | Pharmicell's last 12 months EBITDA is $16.6M. |
| What is Pharmicell's EBITDA margin? | Pharmicell's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Pharmicell? | Current EBITDA multiple of Pharmicell is 30.3x. |
| What is the current FCF of Pharmicell? | Pharmicell's last 12 months FCF is $3.4M. |
| What is Pharmicell's FCF margin? | Pharmicell's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Pharmicell? | Current FCF multiple of Pharmicell is 148.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
